Skip to content
Oncology Research Hub

Dallas, Texas

Cancer clinical trials in Dallas, TX

243 cancer studies are recruiting participants at sites in Dallas as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Dallas at a glance

  • 243 studies are recruiting at a site in Dallas.
  • By phase: Early Phase 1 (3), Phase 1 (52), Phase 1/2 (45), Phase 2 (41), Phase 2/3 (7), Phase 3 (64), Phase 4 (2), No phase (4), Observational (25). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (176), university, hospital or other (56), government (11).
  • By research area: Breast Cancer (73), Lung Cancer (63), Lymphoma (42), Prostate Cancer (35), Pancreatic Cancer (17), Melanoma (13).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Dallas

Basic details from each study's public record (the 30 most recently updated of 243). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study site
    UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT03418961 · updated
  2. Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

    • No phase
    • Ages 18 to 80
    • Female participants
    Sponsor
    Deborah Farr, MD
    Study site
    UT Southwestern
    Registry record
    NCT05245812 · updated
  3. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT05564377 · updated
  4. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    University of Texas Southwestern Medical Center
    Registry record
    NCT06638307 · updated
  5. Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - DFW ( Site 8000)
    Registry record
    NCT06797635 · updated
  6. A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study sites
    Baylor Scott & White Research Institute -Texas Oncology · UT Southwestern Medical Center
    Registry record
    NCT06827236 · updated
  7. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - DFW ( Site 8007)
    Registry record
    NCT06841354 · updated
  8. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Texas Oncology - DFW ( Site 8009) · UT Southwestern ( Site 0092)
    Registry record
    NCT06966700 · updated
  9. ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    ALX Oncology Inc.
    Study site
    University of Texas Southwestern Medical Center
    Registry record
    NCT07007559 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Lung cancer studies recruiting in Dallas

  1. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Texas Southwestern Medical Center
    Study site
    University of Texas Southwestern Medical Center
    Registry record
    NCT02468024 · updated
  2. LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    NovoCure GmbH
    Study sites
    Old Parkland Hospital Hematology Oncology Clinic · UT Southwestern Medical Center
    Registry record
    NCT06216301 · updated
  3. Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - DFW ( Site 8003)
    Registry record
    NCT06780098 · updated
  4. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    UT Southwestern Medical Center Simmons Comprehensive Cancer Center
    Registry record
    NCT07063745 · updated
  5. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT04267848 · updated
  6. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Mary Crowley Cancer Research Center
    Registry record
    NCT04886804 · updated
  7. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT06096844 · updated
  8. Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study sites
    NEXT Dallas · START Dallas- Fort Worth
    Registry record
    NCT07080242 · updated
  9. Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Texas Oncology - DFW
    Registry record
    NCT07680790 · updated
  10. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Texas Oncology - DFW ( Site 8103) · UT Southwestern Medical Center ( Site 0190)
    Registry record
    NCT06623422 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Prostate cancer studies recruiting in Dallas

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT04423211 · updated
  2. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT03866382 · updated
  3. Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT05691465 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Melanoma studies recruiting in Dallas

  1. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    • Phase 1/2
    • From 6 months, up to 17 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Call for Information (Investigational Site 0054)
    Registry record
    NCT02332668 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Dallas, TX on ClinicalTrials.gov.

Lymphoma studies recruiting in Dallas

  1. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    The University of Texas Southwestern Medical Center
    Registry record
    NCT07221500 · updated
  2. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - DFW ( Site 8000)
    Registry record
    NCT06717347 · updated
  3. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UT Southwestern Medical Center ( Site 0190)
    Registry record
    NCT06890884 · updated
  4. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Medical City Dallas Hospital · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT04546399 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Medical City Dallas Hospital · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT05675410 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Dallas, TX on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Dallas

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US067
    Registry record
    NCT07522073 · updated
  2. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT04858334 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Ask about studies near Dallas

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call